1. Introduction

Incorporating a biotechnology startup in Australia requires compliance with company incorporation law, intellectual property protection, biotechnology-specific regulatory controls, biosafety rules, employment law, tax obligations and, where applicable, therapeutic goods, clinical trial, genetic technology and foreign investment regulations.

The most common structure is a proprietary company limited by shares (Pty Ltd) registered with the Australian Securities and Investments Commission (ASIC). This structure is generally suitable for startups developing pharmaceuticals, medical devices, diagnostics, gene therapies, agricultural biotechnology, synthetic biology, research tools and laboratory technologies.

An important distinction is that incorporating a company does not itself authorise it to conduct every biotechnology activity. A company may be legally incorporated yet still require separate approvals, licences, certifications or institutional permissions before conducting research, manufacturing products, handling genetically modified organisms (GMOs), running clinical trials or marketing therapeutic goods.

This explanation focuses on Australian federal law and relevant state and territory legislation, with comparative case law where judicial decisions from other jurisdictions provide useful guidance.

2. Principal legal framework

The principal legislation and regulatory institutions include the following.

Other relevant regimes include the Research Involving Human Embryos Act 2002 (Cth), the Prohibition of Human Cloning for Reproduction Act 2002 (Cth), state and territory human tissue laws, clinical trial requirements and export control laws. The applicable rules depend on the startup's technology, activities and location.

3. Choosing the appropriate corporate structure

The founders should determine whether the business should be incorporated as a proprietary company or a public company.

Proprietary company limited by shares — Pty Ltd

Usually appropriate for an early-stage biotech startup. It supports founder ownership, employee equity, angel investment, venture capital financing and licensing arrangements. It generally cannot offer shares to the public and is subject to proprietary-company shareholder limits.

Public company limited by shares

May be appropriate where a biotech business anticipates a public capital raising, a larger investor base or a future stock-market listing. It involves more extensive governance, reporting and fundraising requirements.

ASIC confirms that a proprietary company must have at least one shareholder and one director, with at least one director ordinarily resident in Australia. A company secretary is optional for an ordinary proprietary company.

ASIC+2

Advantages of the Pty Ltd structure

Separate legal personality: The company can own laboratory equipment, enter research contracts, hold intellectual property and incur debts in its own name.

Limited liability: Shareholders' liability is generally limited to the amount unpaid on their shares, although directors may incur personal liability in particular circumstances.

Investment flexibility: The company can issue shares to founders and investors, subject to its constitution, shareholder agreements and applicable law.

Continuity: The company's existence is not ordinarily affected by a founder leaving or selling shares.

Commercial credibility: Universities, research institutions, pharmaceutical companies and investors can contract with a defined legal entity.

Relevant case law: Salomon v A Salomon & Co Ltd [1897] AC 22

The House of Lords established the foundational principle that a properly incorporated company is a legal person distinct from its shareholders, even where one individual effectively owns and controls the business.

Application to biotech: If a founder transfers patent rights to the startup and the company enters a licensing agreement, those rights and obligations can belong to the company rather than the founder personally. However, the transfer must actually be documented; incorporation alone does not automatically transfer pre-existing intellectual property.

4. Company name, registration and ACN

The primary registration statute is the Corporations Act 2001 (Cth).

Under sections 117–119, an application is lodged with ASIC and the company comes into existence when ASIC registers it. A proprietary company's registered name ordinarily includes “Pty Ltd” or “Proprietary Limited”. ASIC allocates an Australian Company Number (ACN).

Federal Register of Legislation+1

Step-by-step registration requirements

Select a company name. Check ASIC's register for availability and consider whether the name conflicts with another business or trade mark.

Choose the company type. For most early-stage ventures, consider a proprietary company limited by shares.

Identify directors and shareholders. Decide who will manage the business and who will own the equity.

Determine the share structure. Set the number and class of shares, their issue price and the initial allocation to each shareholder.

Choose governance rules. Adopt the statutory replaceable rules, a constitution or an appropriate combination, subject to the company's circumstances.

Obtain required consents and director IDs. Obtain the required written consents and ensure each director has applied for a director identification number before appointment.

Lodge the application with ASIC. Registration can be undertaken through the Australian Government's Business Registration Service or another authorised process.

Retain the registration documents. Keep the certificate of registration, ACN, share records, governance documents and consent records.

Official resources: ASIC — Register a company and Business Registration Service.

Case law: Corporations Act 2001 and pre-incorporation contracts

Section 131 regulates contracts entered into on behalf of a company before it is registered. A person purporting to act for the proposed company may face personal liability if the company is not registered or fails to ratify the contract in accordance with the statutory framework.

Biotech example: A founder signs a two-year laboratory lease in the name of a proposed biotech company before ASIC registers it. The founder should not assume the company automatically becomes the contracting party. The agreement should clearly address pre-incorporation liability and the steps needed for the company to adopt the contract.

5. Directors, shareholders and governance

A. Director eligibility

For a proprietary company, the essential requirements generally include:

At least one director who ordinarily resides in Australia.

Directors who are at least 18 years old and legally eligible to act.

Written and signed consent to appointment.

A director ID obtained before appointment.

Compliance with restrictions affecting disqualified persons, including applicable insolvency-related restrictions.

These requirements are explained in ASIC's guidance on company officeholders and director IDs.

ASIC+1

A founder based overseas can potentially own shares in an Australian company. However, the Australian-resident director requirement remains important, and foreign ownership may trigger additional investment or sector-specific considerations.

B. Directors' statutory duties

Directors must consider the duties imposed by the Corporations Act, including:

Section 180: care and diligence.

Section 181: good faith and proper purpose.

Section 182: prohibition on improper use of position.

Section 183: prohibition on improper use of information.

Section 191: disclosure of certain material personal interests.

Section 588G: duty to prevent insolvent trading in the circumstances covered by the provision.

These duties are especially important in biotech, where research takes years, clinical trials can be expensive and commercial milestones may be uncertain.

Case law: Daniels v Anderson (1995) 37 NSWLR 438

The New South Wales Court of Appeal emphasised that directors have duties to exercise appropriate care and diligence and cannot simply remain uninformed about the company's affairs.

Application: A biotech director should monitor cash runway, clinical trial expenditure, regulatory milestones, laboratory safety risks, research integrity and the status of critical intellectual property. A scientific founder's expertise does not replace the need for sound financial and corporate oversight.

Case law: Australian Securities and Investments Commission v Adler [2002] NSWSC 171

The case concerned breaches of directors' duties and misuse of corporate power in connection with transactions involving HIH Insurance.

Application: Biotech founders must distinguish personal interests from corporate interests. A company should document related-party transactions, payments to founder-owned laboratories, licensing arrangements and investments involving associated entities. Transactions should be properly approved and supported by appropriate disclosure and records.

6. Share capital, founders' equity and investment

The founders should establish an ownership structure that is clear from the first day of operation.

For example, a startup might issue ordinary shares to its founders and later establish an employee share scheme or issue additional shares to investors. The exact arrangement should reflect the founders' contributions, funding plans, intellectual property ownership and future dilution.

Important documents include:

A share subscription or founder share agreement.

A shareholders' agreement addressing voting, transfers, reserved matters, exits and deadlock.

A company constitution, where appropriate.

Employee share scheme documents, if used.

IP assignment and confidentiality agreements.

Investment agreements covering representations, warranties, governance rights and future funding.

A shareholders' agreement is particularly important when founders contribute different assets. One founder may contribute laboratory research, another may provide capital, and another may contribute software or commercial expertise. Their respective contributions should be properly documented rather than left to informal understandings.

Foreign investment considerations

Foreign founders and investors may invest in Australian biotech companies, but the Foreign Acquisitions and Takeovers Act 1975 (Cth) and associated rules may apply to certain acquisitions, interests or transactions.

Whether notification or approval is required depends on factors such as the investor, ownership interest, transaction value, applicable thresholds and whether the company is involved in a sensitive or nationally significant activity.

A foreign investor should assess the rules before completing a transaction rather than assume that ordinary company registration resolves the issue.

7. Intellectual property protection for biotech startups

Intellectual property (IP) is often the most valuable asset of a biotechnology company. Before fundraising or commencing collaborative research, the founders should establish who owns the technology and whether the company has the right to commercialise it.

A. Patents and biological inventions

Under the Patents Act 1990 (Cth), an invention must satisfy the relevant patentability requirements, including novelty, inventive step, usefulness and patentable subject matter.

Examples of potentially patentable biotechnology inventions include:

Genetically modified organisms and engineered cells.

Recombinant proteins and certain isolated biological materials.

Laboratory methods, diagnostic methods and manufacturing processes.

Genetic vectors, engineered enzymes and synthetic biological systems.

Patentability is claim-specific. Not every discovery, naturally occurring biological characteristic or genetic sequence is patentable. IP Australia's guidance explains the additional considerations for biological inventions.

IP Australia

Leading Australian case: D'Arcy v Myriad Genetics Inc [2015] HCA 35

High Court of Australia · 7 October 2015

The High Court held that the isolated nucleic acid claims at issue, concerning the BRCA1 gene and associated cancer susceptibility, were not patentable subject matter under Australian law. The Court considered the substance of the claimed invention and its relationship to naturally occurring genetic information.

High Court of Australia+1

Legal significance: A biotech startup cannot assume that isolating a biological material or identifying a naturally occurring genetic sequence will automatically produce a patentable invention.

Practical implications:

Obtain patent advice before publicly disclosing a discovery.

Identify the actual technical contribution of the invention.

Document inventorship and assignments from founders, employees and contractors.

Conduct freedom-to-operate searches before commercial development.

Protect confidential know-how through appropriate access controls and confidentiality agreements.

B. University research and ownership disputes

A common incorporation problem arises when founders developed their technology at a university, hospital, research institute or previous employer.

The company should review employment agreements, research grants, institutional IP policies, collaboration agreements and material transfer agreements. A founder's status as the scientist who made a discovery does not necessarily establish personal ownership of the resulting IP.

For example, a company formed around a university-developed gene therapy may require a formal licence from the university before it can commercialise the technology. The licence should address royalties, milestone payments, sublicensing, patent prosecution, improvements and termination.

C. Trade marks, copyright and confidential information

Patent protection is only one part of the IP strategy.

Trade marks: Protect the company and product brands.

Copyright: May protect software, research reports, databases and certain documentation, subject to the applicable law.

Trade secrets: Protect confidential manufacturing processes, assay parameters, formulations and research know-how when confidentiality is maintained.

Contracts: Clarify ownership of inventions developed by employees, consultants and research partners.

8. Biotechnology-specific licences and regulatory approvals

This is the stage where biotech incorporation differs most significantly from incorporating an ordinary consultancy or retail business.

A. Genetically modified organisms

The Gene Technology Act 2000 (Cth) establishes a regulatory framework administered by the Office of the Gene Technology Regulator (OGTR).

Under the framework, dealings with GMOs must be authorised through an applicable category, which may include an exempt dealing, a notifiable low risk dealing, a dealing authorised under the GMO Register or a licence. The correct category depends on the activity and risk classification.

Office of the Gene Technology Regulator+1

Activities potentially covered include:

Research and laboratory experimentation.

Manufacture and production involving GMOs.

Transport and importation.

Environmental release and field trials.

Destruction of GMOs.

Some activities require an accredited organisation, an Institutional Biosafety Committee (IBC), a certified containment facility or a specific licence.

Example: A startup engineering bacteria to manufacture a therapeutic protein must determine the regulatory classification of its GMO dealings before commencing the relevant work. Company registration alone does not authorise the laboratory activity.

Official guidance: OGTR — Apply for GMO approval.

B. Medicines, biologicals and medical devices

The Therapeutic Goods Act 1989 (Cth) regulates many therapeutic products supplied in Australia.

The Therapeutic Goods Administration (TGA) regulates different product categories under different requirements. The startup must establish whether its product is a medicine, biological, medical device, another regulated therapeutic good or a product outside that framework.

Regulatory pathways by product type

Medicines and biologicals

Market supply generally requires the relevant Australian Register of Therapeutic Goods (ARTG) authorisation, unless an applicable exemption or alternative legal pathway applies. Manufacturing licences and good manufacturing practice (GMP) obligations may also apply.

Dimension Vista 500 & 1500 Intelligent Lab Systems - Siemens Healthineers

Medical devices and diagnostics

Determine whether the product is a regulated medical device or an in-vitro diagnostic medical device (IVD), identify its classification and establish the relevant conformity assessment and ARTG requirements.

Cell and Gene Therapy CDMO Services - OmniaBio

Cell and gene therapies

Assess the biological or medicine classification, clinical trial pathway, manufacturing requirements and any additional OGTR requirements applicable to genetically modified therapeutic products.

The TGA states that therapeutic goods generally require the relevant market authorisation before supply, and Australian manufacturers of regulated therapeutic goods may require a manufacturing licence or conformity assessment certificate.

Therapeutic Goods Administration (TGA)+2

Official resources:

TGA — Supplying therapeutic goods

TGA — Manufacturing

C. Clinical trials

If a startup intends to test an unapproved therapeutic good in humans, it must determine whether the Clinical Trial Notification (CTN) or Clinical Trial Approval (CTA) pathway applies.

The CTN pathway involves notification through the relevant process and review by a Human Research Ethics Committee (HREC). The CTA pathway involves an application to the TGA and regulatory evaluation. Additional requirements may apply to particular biologicals, gene therapies and GMO clinical trials.

Therapeutic Goods Administration (TGA)+1

A clinical-stage startup should allocate responsibility for:

Ethics approval and trial governance.

Informed consent and participant protections.

Trial sponsorship and investigator agreements.

Product quality and manufacturing compliance.

Safety reporting, data management and monitoring.

Insurance and indemnity arrangements.

A trial sponsor should not assume that incorporation, ethics approval or one regulatory notification automatically satisfies every other applicable legal requirement.

9. Laboratory safety, biosecurity and privacy

A. Work health and safety

Laboratory operations may be subject to the applicable state or territory work health and safety legislation, regulations and codes, together with specific Commonwealth laws where relevant.

The startup should establish appropriate controls for biological hazards, chemical exposure, laboratory waste, staff training, incident reporting and emergency procedures.

The applicable regulator and precise obligations depend on the jurisdiction and nature of the work.

B. Biosecurity

The Biosecurity Act 2015 (Cth) and related instruments may apply to imported biological materials, microorganisms, animal products, laboratory specimens and other regulated goods.

Before importing biological samples, a startup should check whether permits, approved conditions, treatment requirements or other restrictions apply. Customs clearance alone should not be treated as proof that every biosecurity requirement has been met.

C. Genetic and health information

Biotech companies working with human genetic samples, patient records or clinical trial data should assess their obligations under the Privacy Act 1988 (Cth), the Australian Privacy Principles where applicable, and relevant state or territory privacy and health-records laws.

The company should address:

The legal basis for collecting and using personal information.

Consent and permitted secondary research uses.

Access controls, security and retention.

Data sharing with universities, sponsors and overseas partners.

Breach response and applicable notification obligations.

Genetic information can be commercially valuable, but it can also create significant privacy and ethical risks.

10. Tax registration, R&D incentives and financial compliance

Incorporation should be followed by appropriate tax and financial arrangements.

A. Australian Business Number and tax registrations

Depending on the business, the company may need:

An Australian Business Number (ABN).

A tax file number (TFN).

Goods and Services Tax (GST) registration when required or voluntarily chosen where permitted.

Pay As You Go (PAYG) withholding registration if applicable.

Payroll tax registration in relevant jurisdictions when applicable.

Workers' compensation insurance and superannuation compliance for employees.

The applicable thresholds and requirements should be checked against current Australian Taxation Office (ATO) and state or territory guidance.

B. Research and Development Tax Incentive

Eligible biotechnology companies may qualify for the Australian R&D Tax Incentive. Eligibility is not automatic merely because expenditure is described as scientific research.

The startup should determine whether its activities satisfy the applicable R&D definitions, maintain contemporaneous records, distinguish eligible R&D expenditure from other spending and meet the registration and tax-claim requirements.

Records should connect the technical work to the underlying hypotheses, experiments, observations, results and conclusions.

C. Insolvency and directors' responsibility

Biotechnology businesses frequently operate with high research costs and delayed revenue. Directors should maintain credible cash-flow forecasts, monitor funding conditions and respond promptly to financial distress.

A limited-liability company does not eliminate directors' statutory duties or potential personal liability for breaches.

11. Employment, research collaborations and commercial contracts

Before hiring researchers or entering collaborations, the company should document the relationship between the parties.

Important agreements include:

A critical issue is publication. Academic researchers may want to publish findings, whereas a startup may need time to file patent applications. Collaboration agreements should establish a review procedure that balances publication rights with legitimate confidentiality and patent-filing needs.

12. Further case law relevant to biotech incorporation

The following decisions provide useful principles for structuring and operating a biotechnology company. Not all concern biotechnology directly; their relevance lies in the corporate, IP or commercial issues they address.

Applying the case law in practice

Consider a startup formed by two scientists and an investor. The scientists contribute a diagnostic technology developed during university research, while the investor funds commercial development.

The founders should:

Verify ownership and inventorship before assigning the technology.

Incorporate the company and document the share allocations.

Obtain a valid assignment or licence from the actual IP owner.

Ensure directors manage conflicts and monitor financial sustainability.

Establish a regulatory pathway before clinical use or commercial supply.

Document research collaboration, confidentiality and data-handling arrangements.

These steps translate the general principles from corporate and IP law into a workable incorporation strategy.

13. Incorporation compliance checklist

Startup readiness checklist

0/20

Corporate formation

Choose a company name and register with ASIC

Appoint an eligible Australian-resident director

Obtain director IDs and written consents

Decide share structure and initial shareholders

Adopt appropriate governance rules and maintain registers

Intellectual property

Identify inventors and verify IP ownership

Execute founder, employee and contractor IP assignments

Review university and research institution obligations

Assess patentability and freedom to operate

Implement confidentiality and publication controls

Biotech regulation

Classify the intended research and commercial activities

Assess OGTR approvals and containment requirements

Determine TGA, ARTG and manufacturing obligations

Obtain applicable clinical trial and ethics approvals

Review laboratory safety, biosecurity and privacy requirements

Finance and operations

Obtain applicable ABN and tax registrations

Establish accounting and cash-flow controls

Assess R&D Tax Incentive eligibility

Arrange appropriate insurance

Implement contracts, quality systems and ongoing compliance reviews

Reset checklistCopy checklist

14. Conclusion

Incorporating a biotech startup in Australia is a two-stage legal exercise: first, establish the company correctly; second, secure the rights and regulatory permissions needed to carry out its specific activities.

For most early-stage ventures, a Pty Ltd structure provides a practical starting point. The more difficult legal questions often concern patent ownership, university-derived inventions, GMO approvals, clinical trials, therapeutic goods regulation, investor rights and directors' responsibilities.

The principal authorities include the Corporations Act 2001 (Cth), the Patents Act 1990 (Cth), the Gene Technology Act 2000 (Cth) and the Therapeutic Goods Act 1989 (Cth), together with decisions such as Salomon, Daniels v Anderson, ASIC v Adler and D'Arcy v Myriad Genetics.

Because regulatory requirements depend on the product and research activity, founders should obtain Australian corporate and specialist regulatory advice before beginning regulated laboratory work or making a therapeutic product commercially available.

This is general legal information, not a substitute for advice on a specific company or biotechnology product.